Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

Studied

Randomized trial comparing tirzepatide with placebo for cardiovascular death or worsening heart failure, and patient-reported health status.

Who / model

731 people with obesity and heart failure with preserved ejection fraction; median follow-up was 104 weeks, with health-status assessment at 52 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The first primary outcome occurred in 9.9% versus 15.3%. Worsening heart failure occurred in 8.0% versus 14.2%; cardiovascular deaths were 2.2% versus 1.4%. The other primary outcome, health-status score, improved 19.5 versus 12.7 points. Adverse events, mainly digestive, led to stopping treatment in 6.3% versus 1.4%.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary